Wanbury's Q1 Profit Soars to ₹135 Crore, Revenue Climbs to ₹1.6 Billion Aug 05, 2025
Wanbury Limited Reports Strong Q1 Results, Approves ESOP Grants and Director Reappointment Aug 04, 2025
More news about Wanbury
27Jun 25
Wanbury Unveils 'Wanbury Cred': A Revolutionary Iron Supplement to Combat Anemia
Wanbury Limited has introduced 'Wanbury Cred', a new iron supplement designed to combat iron deficiency and anemia. The product boasts an improved safety profile and enhanced absorption compared to existing supplements. This launch represents Wanbury's strategic move to expand its presence in the nutritional supplement market and address a significant global health issue.
20May 25
Wanbury Secures Brazilian FDA Approval for Maharashtra Manufacturing Facility
Wanbury Limited has obtained a Good Manufacturing Practices (GMP) certificate from ANVISA, Brazil's health regulatory agency, for its Patalganga, Maharashtra facility. This certification, known as CBPF, validates the facility's compliance with Brazilian quality standards for pharmaceutical manufacturing. The approval positions Wanbury to expand its presence in the Brazilian market, one of Latin America's largest, and potentially facilitates easier approvals in other countries recognizing ANVISA certifications.
23Apr 25
Wanbury Limited Embarks on Digital Transformation with SAP S/4 HANA Implementation
Wanbury Limited, a pharmaceutical company, has announced the implementation of SAP S/4 HANA Private Cloud Platform to enhance its digital capabilities. The system aims to improve processes in finance, sales, production, quality, material management, and compliance. Partnering with Deloitte Consulting, Wanbury expects this move to drive operational excellence, foster innovation, and support sustainable growth. The implementation is scheduled for the current financial year.
06Mar 25
Wanbury Limited Slashes Interest Costs with ₹175 Crore Debt Refinancing
Wanbury Limited has successfully refinanced ₹175 crore of existing debt through Emerging India Credit Opportunities Fund II. The new deal features a 12.5% per annum interest rate, down from 21% on previous NCDs, with a 5-year tenure and 9-month moratorium. The refinancing includes repurchase of ₹95 crore NCDs and refinancing of ₹150 crore existing debt. This move is expected to significantly reduce Wanbury's interest burden and improve its financial health.